Scientists have found that a subset of CD8<sup>+</sup> T cells in the brain lessens the activation of microglia and limits disease pathology in a model of Alzheimer's disease.
KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can t bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.
LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research.
Immunotherapy has the potential to eliminate tumors, but works best for select patients. Engineering T cells to bypass cancer’s defenses could help expand treatment eligibility to more patients.